{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:56:10Z","timestamp":1788216970604,"version":"build-2803163510"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"German Federal Institute for Drugs and Medical Devices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>Is the failure of the selective progesterone receptor modulator ulipristal acetate (UPA) as emergency contraception (EC; 30\u00a0mg, single) or inadvertent exposure for myoma treatment (5\u00a0mg\/d) in pregnancy associated with a higher risk of birth defects, spontaneous abortion (SAB) or elective termination of pregnancy (ETOP)?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>We did not find an increased risk for birth defects, SABs or ETOPs after UPA exposure during implantation and early embryogenesis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>Pregnancy outcome data after exposure to UPA are very limited. In cases of EC failure or unplanned pregnancy during myoma treatment, women need well-grounded risk assessment to minimize anxiety and prevent unjustified termination of pregnancy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>Observational study of prospectively ascertained pregnancies from the German Embryotox institute with UPA exposure (EC, n\u00a0=\u200995; myoma, n\u00a0=\u20097). Four retrospectively reported pregnancy outcomes were evaluated separately.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>A total of 226 requests on ulipristal were directed to the German Embryotox institute during the study period 2010\u20132018. Outcomes of pregnancies exposed\u2014(i) precycle, (ii) preconceptional or (iii) first trimester\u2014were ascertained using standardized questionnaires. Descriptive statistics were applied.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>Failed EC with UPA resulted in 95 prospectively ascertained pregnancies, of which 56 had completed follow-up: 37 live births, 7 SABs and 12 ETOPs. There was no major birth defect. Just 34% of women had taken UPA during the fertile window. Seven prospectively enrolled pregnancies were treated for myoma and had known pregnancy outcomes: five healthy live births and two SABs. Among the four retrospectively reported pregnancies after EC, there was one child diagnosed with Beckwith-Wiedemann syndrome (BWS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>Our limited sample size does not allow concluding safety of UPA use in pregnancy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>We provide a preliminary basis for reassuring women who wish to carry their pregnancy to term after EC or myoma treatment with UPA. However, because of the report of a BWS after UPA exposure, a possible epigenetic effect could not be excluded and requires further evaluation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>This work was performed with financial support from the German Federal Institute for Drugs and Medical Devices (BfArM). All authors declare that they have no conflicts of interest.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>Registered with the German Clinical Trial Register (DRKS00015155).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/deaa024","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T04:29:39Z","timestamp":1582259379000},"page":"751-758","source":"Crossref","is-referenced-by-count":7,"title":["Ulipristal acetate and pregnancy outcome\u2014an observational study"],"prefix":"10.1093","volume":"35","author":[{"given":"Jenny Katharina","family":"Wagner","sequence":"first","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Pharmakovigilanz- und Beratungszentrum f\u00fcr Embryonaltoxikologie, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Dathe","sequence":"first","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Pharmakovigilanz- und Beratungszentrum f\u00fcr Embryonaltoxikologie, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Schaefer","sequence":"first","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Pharmakovigilanz- und Beratungszentrum f\u00fcr Embryonaltoxikologie, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2451-4247","authenticated-orcid":false,"given":"Maria","family":"Hoeltzenbein","sequence":"first","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Pharmakovigilanz- und Beratungszentrum f\u00fcr Embryonaltoxikologie, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"2020043013361577600_ref1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/bdra.23029","article-title":"The all-or-none phenomenon revisited","volume":"94","author":"Adam","year":"2012","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"2020043013361577600_ref2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.reprotox.2016.11.019","article-title":"Who seeks Teratology Information Service\u2019s advice? Assessing the risk of selection bias in observational cohort studies on drug risks in pregnancy","volume":"67","author":"Beck","year":"2017","journal-title":"Reprod Toxicol"},{"key":"2020043013361577600_ref3","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1517\/14656566.9.14.2459","article-title":"Selective progesterone receptor modulators 1: use during pregnancy","volume":"9","author":"Benagiano","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"2020043013361577600_ref4","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1517\/14656566.2014.914494","article-title":"Selective progesterone receptor modulators: an update","volume":"15","author":"Benagiano","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"2020043013361577600_ref5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jcu.1031","article-title":"Outcome of pregnancies in women with uterine leiomyomas identified by sonography in the first trimester","volume":"29","author":"Benson","year":"2001","journal-title":"J Clin Ultrasound"},{"key":"2020043013361577600_ref6","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/humrep\/dev030","article-title":"Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system","volume":"30","author":"Berger","year":"2015","journal-title":"Hum Reprod"},{"key":"2020043013361577600_ref7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/uog.12442","article-title":"Miscarriage in contemporary maternal-fetal medicine: targeting clinical dilemmas","volume":"42","author":"Borrell","year":"2013","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2020043013361577600_ref8","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.contraception.2013.05.010","article-title":"Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens","volume":"88","author":"Brache","year":"2013","journal-title":"Contraception"},{"key":"2020043013361577600_ref9","first-page":"2785","article-title":"A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception","volume":"30","author":"Brache","year":"2015","journal-title":"Hum Reprod"},{"key":"2020043013361577600_ref10","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1093\/humrep\/deq157","article-title":"Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture","volume":"25","author":"Brache","year":"2010","journal-title":"Hum Reprod"},{"key":"2020043013361577600_ref11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nrendo.2017.166","article-title":"Expert consensus document: clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement","volume":"14","author":"Brioude","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2020043013361577600_ref12","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1111\/1471-0528.14773","article-title":"Current controversies with oral emergency contraception","volume":"124","author":"Cameron","year":"2017","journal-title":"BJOG"},{"key":"2020043013361577600_ref13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.fertnstert.2004.07.964","article-title":"Association between Beckwith-Wiedemann syndrome and assisted reproductive technology: a case series of 19 patients","volume":"83","author":"Chang","year":"2005","journal-title":"Fertil Steril"},{"key":"2020043013361577600_ref14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00228-017-2351-y","article-title":"Drug safety in pregnancy: the German Embryotox institute","volume":"74","author":"Dathe","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"2020043013361577600_ref15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0038-1675780","article-title":"Assisted reproductive technology and epigenetics","volume":"36","author":"DeAngelis","year":"2018","journal-title":"Semin Reprod Med"},{"key":"2020043013361577600_ref16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1530\/REP-12-0237","article-title":"Genomic imprints as a model for the analysis of epigenetic stability during assisted reproductive technologies","volume":"144","author":"Denomme","year":"2012","journal-title":"Reproduction"},{"key":"2020043013361577600_ref17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.fertnstert.2015.09.032","article-title":"Long-term medical management of uterine fibroids with ulipristal acetate","volume":"105","author":"Donnez","year":"2016","journal-title":"Fertil Steril"},{"key":"2020043013361577600_ref18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","article-title":"Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids","volume":"103","author":"Donnez","year":"2015","journal-title":"Fertil Steril"},{"key":"2020043013361577600_ref19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"2020043013361577600_ref20","article-title":"CHMP assessment report for ellaone","author":"EMA","year":"2009"},{"key":"2020043013361577600_ref21","article-title":"Assessment report ellaOne","author":"EMA","year":"2014"},{"key":"2020043013361577600_ref22","article-title":"Esmya: new measures to minimise risk of rare but serious liver injury","author":"EMA","year":"2018"},{"key":"2020043013361577600_ref23","article-title":"ellaOne: EPAR-product information","author":"EMA","year":"2019"},{"key":"2020043013361577600_ref24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.fertnstert.2012.12.047","article-title":"Ovulation induction and epigenetic anomalies","volume":"99","author":"Fauque","year":"2013","journal-title":"Fertil Steril"},{"key":"2020043013361577600_ref25","article-title":"Approval letter Ella (ulipristal acetate)","author":"FDA","year":"2010"},{"key":"2020043013361577600_ref26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/AOG.0b013e3181c8e2aa","article-title":"Ulipristal acetate taken 48\u2013120 hours after intercourse for emergency contraception","volume":"115","author":"Fine","year":"2010","journal-title":"Obstet Gynecol"},{"key":"2020043013361577600_ref27","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jogc.2018.05.020","article-title":"Pregnancy outcomes following ulipristal acetate for uterine fibroids: a systematic review","volume":"40","author":"De Gasperis-Brigante","year":"2018","journal-title":"J Obstet Gynaecol Can"},{"key":"2020043013361577600_ref28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3109\/09513590.2014.950645","article-title":"The rationale for use of ulipristal acetate as first line in emergency contraception: biological and clinical evidence","volume":"30","author":"Glasier","year":"2014","journal-title":"Gynecol Endocrinol"},{"key":"2020043013361577600_ref29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(10)60101-8","article-title":"Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis","volume":"375","author":"Glasier","year":"2010","journal-title":"Lancet"},{"key":"2020043013361577600_ref30","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.contraception.2013.03.009","article-title":"Letter to the editor: K. Gemzell-Danielsson et\u00a0al. Emergency contraception\u2014mechanisms of action","volume":"88","author":"Hillemanns","year":"2013","journal-title":"Contraception"},{"key":"2020043013361577600_ref31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jcpt.12590","article-title":"Spontaneous pregnancy during ulipristal acetate treatment of giant uterine leiomyoma","volume":"43","author":"Hrgovic","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"2020043013361577600_ref32","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/1471-0528.15240","article-title":"Epigenetics and reproductive medicine: scientific impact paper no. 57","volume":"125","author":"Huntriss","year":"2018","journal-title":"BJOG"},{"key":"2020043013361577600_ref33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.contraception.2016.05.002","article-title":"Safety and effectiveness data for emergency contraceptive pills among women with obesity: a systematic review","volume":"94","author":"Jatlaoui","year":"2016","journal-title":"Contraception"},{"key":"2020043013361577600_ref34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1345\/aph.1Q248","article-title":"Ulipristal acetate: contraceptive or contragestive?","volume":"45","author":"Keenan","year":"2011","journal-title":"Ann Pharmacother"},{"key":"2020043013361577600_ref35","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.bpobgyn.2008.01.009","article-title":"Impact of fibroids on reproductive function","volume":"22","author":"Khaund","year":"2008","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2020043013361577600_ref36","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00404-016-4253-0","article-title":"Experience with oral emergency contraception since the OTC switch in Germany","volume":"295","author":"Kiechle","year":"2017","journal-title":"Arch Gynecol Obstet"},{"key":"2020043013361577600_ref37","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/humupd\/dmu033","article-title":"A systematic review and meta-analysis of DNA methylation levels and imprinting disorders in children conceived by IVF\/ICSI compared with children conceived spontaneously","volume":"20","author":"Lazaraviciute","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2020043013361577600_ref38","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.contraception.2014.01.003","article-title":"Ulipristal acetate for emergency contraception: postmarketing experience after use by more than 1 million women","volume":"89","author":"Levy","year":"2014","journal-title":"Contraception"},{"key":"2020043013361577600_ref39","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1093\/humrep\/dex328","article-title":"Effect of ulipristal acetate and mifepristone at emergency contraception dose on the embryo-endometrial attachment using an in vitro human trophoblastic spheroid and endometrial cell co-culture model","volume":"32","author":"Li","year":"2017","journal-title":"Hum Reprod"},{"key":"2020043013361577600_ref40","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/humrep\/14.7.1735","article-title":"Myomectomy: a retrospective study to examine reproductive performance before and after surgery","volume":"14","author":"Li","year":"1999","journal-title":"Hum Reprod"},{"key":"2020043013361577600_ref41","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.fertnstert.2014.07.1253","article-title":"First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids","volume":"102","author":"Luyckx","year":"2014","journal-title":"Fertil Steril"},{"key":"2020043013361577600_ref42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/hmg\/ddp465","article-title":"Dual effects of superovulation: loss of maternal and paternal imprinted methylation in a dose-dependent manner","volume":"19","author":"Market-Velker","year":"2010","journal-title":"Hum Mol Genet"},{"key":"2020043013361577600_ref43","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2147\/IJWH.S25887","article-title":"Immunopharmacology of ulipristal as an emergency contraceptive","volume":"3","author":"Miech","year":"2011","journal-title":"Int J Women\u2019s Health"},{"key":"2020043013361577600_ref44","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1933719113519178","article-title":"Ulipristal acetate: critical review about endometrial and ovulatory effects in emergency contraception","volume":"21","author":"Mozzanega","year":"2014","journal-title":"Reprod Sci"},{"key":"2020043013361577600_ref45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jogc.2015.11.004","article-title":"Spontaneous pregnancy following ulipristal acetate treatment in a woman with a symptomatic uterine fibroid","volume":"38","author":"Murad","year":"2016","journal-title":"J Obstet Gynaecol Can"},{"key":"2020043013361577600_ref46","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-4311","article-title":"Assisted reproductive techniques and risk of Beckwith-Wiedemann syndrome","volume":"140","author":"Mussa","year":"2017","journal-title":"Pediatrics"},{"key":"2020043013361577600_ref47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/15513815.2017.1303010","article-title":"Pregnancy outcomes following ulipristal acetate emergency contraception failure: a report of five cases","volume":"36","author":"Ozturk","year":"2017","journal-title":"Fetal Pediatr Pathol"},{"key":"2020043013361577600_ref48","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e1492","article-title":"Emergency contraception","volume":"344","author":"Prabakar","year":"2012","journal-title":"BMJ"},{"key":"2020043013361577600_ref49","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMcp1406328","article-title":"Clinical practice. Emergency contraception","volume":"372","author":"Raymond","year":"2015","journal-title":"N Engl J Med"},{"key":"2020043013361577600_ref50","first-page":"32","article-title":"Case report: successful pregnancy after combined preoperative pretreatment with ulipristal acetate and laparoscopic myoma enucleation in deep-seated cervical posterior wall myoma and desire to have children","volume":"25","author":"R\u00f6mer","year":"2015","journal-title":"J Gyn\u00e4kologische Endokrinologie"},{"key":"2020043013361577600_ref51","first-page":"315","article-title":"Mechanism of action of ulipristal acetate for emergency contraception: a systematic review","volume":"6","author":"Rosato","year":"2015","journal-title":"Front Pharmacol"},{"key":"2020043013361577600_ref52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/13625187.2016.1269162","article-title":"Awareness and knowledge regarding emergency contraception in Berlin adolescents","volume":"22","author":"von Rosen","year":"2017","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"2020043013361577600_ref53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.reprotox.2008.05.064","article-title":"Using observational cohort data for studying drug effects on pregnancy outcome\u2014methodological considerations","volume":"26","author":"Schaefer","year":"2008","journal-title":"Reprod Toxicol"},{"key":"2020043013361577600_ref54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0010-7824(02)00310-4","article-title":"Estimating the efficacy of emergency contraception\u2014how reliable are the data?","volume":"66","author":"Stirling","year":"2002","journal-title":"Contraception"},{"key":"2020043013361577600_ref55","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0010-7824(96)00134-5","article-title":"Effects of two antiprogestins on early pregnancy in the long-tailed macaque (Macaca fascicularis)","volume":"54","author":"Tarantal","year":"1996","journal-title":"Contraception"},{"key":"2020043013361577600_ref56","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1093\/hmg\/dds287","article-title":"Gonadotropin stimulation contributes to an increased incidence of epimutations in ICSI-derived mice","volume":"21","author":"de Waal","year":"2012","journal-title":"Hum Mol Genet"},{"key":"2020043013361577600_ref57","doi-asserted-by":"crossref","first-page":"496","DOI":"10.5114\/pm.2013.39815","article-title":"Pre-treatment with ulipristal acetate before ICSI procedure: a case report","volume":"12","author":"Wdowiak","year":"2013","journal-title":"Menopause Rev"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/35\/4\/751\/33149614\/deaa024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/35\/4\/751\/33149614\/deaa024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T18:25:36Z","timestamp":1588271136000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/35\/4\/751\/5823170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,22]]},"published-print":{"date-parts":[[2020,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deaa024","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,4]]}}}